Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
25 results
  • Melanoma, Kidney Cancer, Lung Cancer, Bladder Cancer, Lymphoma

21-481          Phase I

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma (View details on

  • Head and Neck Cancer, Lung Cancer, Melanoma, Lymphoma

21-258          Phase II

A Multicenter Phase 1-2A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of LNS8801 in Patients With Advanced Cancer With and Without Pembrolizumab (View details on

  • Metastatic/Advanced Cancer, Sarcoma, Breast Cancer, Ovarian Cancer, Leukemia, Head and Neck Cancer, Lymphoma

20-035          Phase II

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors (View details on

  • Lymphoma, Leukemia, Cellular Therapy

22-262          Phase I

A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) (View details on

  • Multiple Myeloma, Lymphoma

21-245          Phase II

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma (View details on

  • Lymphoma, Cellular Therapy

22-383          Phase II

A Phase 1/2, Open-Label, First-in-Human, Multiple Ascending Dose Multicenter Study of MT-101 in Subjects with CD5+ Relapsed/ Refractory Peripheral T Cell Lymphoma (View details on

  • Lymphoma, Hodgkin's Disease

19-113          Phase II

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL) (View details on

  • Cellular Therapy, Lymphoma

21-422          Phase II

A Phase 2 Study of acalabrutinib in combination with lisocabtagene maraleucel in relapsed/refractory aggressive B-cell lymphomas (View details on

Showing 1 - 10 of 25 results